Selegiline transdermal system: In the treatment of major depressive disorder

Drugs

Volumn 67, Issue 2, 2007, Pages 257-265

  Frampton, James E ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CYCLOBENZAPRINE; DEXTROMETHORPHAN; METHADONE; MIRTAZAPINE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; OXCARBAZEPINE; PETHIDINE; PLACEBO; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNINDEXED DRUG;

ANORGASMIA; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; HUMAN; IMPOTENCE; INSOMNIA; LIBIDO DISORDER; LONG TERM CARE; MAJOR DEPRESSION; NONHUMAN; SIDE EFFECT; SINGLE DRUG DOSE; WEIGHT GAIN; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADULT; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; SELEGILINE;

EID: 33846952501     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767020-00006     Document Type: Article

References (23)

1. Holtzheimer PE3rd, Nemeroff CB. Advances in the treatment of depression. NeuroRx 2006 Jan; 3 (1): 42-56
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun 18; 289 (23): 3095-105
3. Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004 May; 184: 386-92
4. Mann JJ. The medical management of depression. N Engl J Med 2005 Oct 27; 353 (17): 1819-34
5. Patkar AA, Pae C-U, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr 2006; 11 (5): 363-75
6. Robinson DS. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull 2002 Summer; 36 (3): 124-38
7. Anderson IM, Nutt DJ, Deakin JFW, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000; 14 (1): 3-20
8. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000 Apr; 157 (4 Suppl.): 1-45
9. Thase ME. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression. J Clin Psychiatry 2006 Apr; 67 (4): 671-2
10. Mahmood I. Selegiline transdermal system Somerset. Curr Opin Investig Drugs 2002 Aug; 3 (8): 1230-3
11. Preskorn SH. Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction of tyramine. J Psychiatric Practice 2006 May; 12 (3): 168-72
12. EMSAM® (selegiline transdermal system) continuous delivery for once-daily application. Prescribing information. Somerset Pharmaceuticals Inc., Tampa (FL). 2006 Apr
13. Gordon MN, Muller CD, Sherman KA, et al. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol Biochem Behav 1999 Jul; 63: 501-6
14. Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 2003 Jan; 55 (1): 27-34
15. Ziemniak JA, Kemper EM, Goodhead M, et al. Pharmacokinetics of selegiline administered via transdermal patch, single oral dose, or intravenous infusion [poster]. New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; 2001 May 29; Phoenix (AZ)
16. Rohatagi S, Barrett JS, DeWitt KE, et al. Multiple dose pharmacokinetics and dose proportionality of selegiline and metabolites in healthy males following transdermal administration [abstract no. PPDM 8441]. Pharm Res 1996 Sep; 13 (Suppl.): S-503
17. Rohatagi S, Barrett JS, McDonald LJ, et al. Selegiline percutaneous absorption in various species and metabolism by human skin. Pharm Res 1997 Jan; 14 (1): 50-5
18. Azzaro AJ, VanDenBerg CM, Blob LF, et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol 2006; 46: 933-44
19. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002 Nov; 159: 1869-75
20. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003 Feb; 64: 208-14
21. Feiger AD, Rickels K, Rynn M, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 2006 Sep; 67 (9): 1354-61
22. Amsterdam JD, Bodkin JA. Selegiline transdermal system (STS) in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006; 26: 1-8
23. FDA approves Emsam (selegiline) as first drug patch for depression [online]. Available from URL: http://www.fda.gov [Accessed 2006 Mar 1]